Novo Nordisk (Denmark) Top Management
NOVO-B Stock | DKK 528.80 15.50 2.85% |
Novo Nordisk employs about 54.4 K people. The company is managed by 10 executives with a total tenure of roughly 126917 years, averaging almost 12691.0 years of service per executive, having 5439.3 employees per reported executive. Analysis of Novo Nordisk's management performance can provide insight into the company performance.
Monique Carter Insider Head VP |
Maziar Doustdar Insider Head VP |
Novo |
Novo Nordisk Management Team Effectiveness
The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.Novo Nordisk Workforce Comparison
Novo Nordisk AS is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 189,080. Novo Nordisk totals roughly 54,393 in number of employees claiming about 29% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.43 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.43. Novo Nordisk AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novo Nordisk AS Price Series Summation is a cross summation of Novo Nordisk price series and its benchmark/peer.
Novo Nordisk Notable Stakeholders
A Novo Nordisk stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novo Nordisk often face trade-offs trying to please all of them. Novo Nordisk's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novo Nordisk's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Monique Carter | Head VP | Profile | |
Maziar Doustdar | Head VP | Profile | |
Lars Jorgensen | CEO Pres | Profile | |
Marcus Schindler | Head EVP | Profile | |
Karsten Knudsen | CFO VP | Profile | |
Henrik Wulff | Head VP | Profile | |
Ludovic Helfgott | Head VP | Profile | |
Camilla Sylvest | Head VP | Profile | |
Douglas Langa | Head VP | Profile | |
Martin Lange | Head VP | Profile |
About Novo Nordisk Management Performance
The success or failure of an entity such as Novo Nordisk AS often depends on how effective the management is. Novo Nordisk management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk operates under Pharmaceuticals And Biosciences classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 45971 people.
Please note, the presentation of Novo Nordisk's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Novo Nordisk's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Novo Nordisk's management manipulating its earnings.
Novo Nordisk Workforce Analysis
Traditionally, organizations such as Novo Nordisk use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novo Nordisk within its industry.Novo Nordisk Manpower Efficiency
Return on Novo Nordisk Manpower
Revenue Per Employee | 3.3M | |
Revenue Per Executive | 17.7B | |
Net Income Per Employee | 1M | |
Net Income Per Executive | 5.6B | |
Working Capital Per Employee | 97.6K | |
Working Capital Per Executive | 530.7M |
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |